GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » ROE %

Ascentage Pharma Group International (HKSE:06855) ROE % : -321.87% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Ascentage Pharma Group International's annualized net income for the quarter that ended in Dec. 2023 was HK$-1,144.7 Mil. Ascentage Pharma Group International's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was HK$355.6 Mil. Therefore, Ascentage Pharma Group International's annualized ROE % for the quarter that ended in Dec. 2023 was -321.87%.

The historical rank and industry rank for Ascentage Pharma Group International's ROE % or its related term are showing as below:

HKSE:06855' s ROE % Range Over the Past 10 Years
Min: -387.58   Med: -90.37   Max: -76.17
Current: -260.12

During the past 8 years, Ascentage Pharma Group International's highest ROE % was -76.17%. The lowest was -387.58%. And the median was -90.37%.

HKSE:06855's ROE % is ranked worse than
91.62% of 1349 companies
in the Biotechnology industry
Industry Median: -43.73 vs HKSE:06855: -260.12

Ascentage Pharma Group International ROE % Historical Data

The historical data trend for Ascentage Pharma Group International's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International ROE % Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial - -80.55 -76.17 -100.19 -387.58

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.90 -75.09 -143.32 -159.80 -321.87

Competitive Comparison of Ascentage Pharma Group International's ROE %

For the Biotechnology subindustry, Ascentage Pharma Group International's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascentage Pharma Group International's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's ROE % distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's ROE % falls into.



Ascentage Pharma Group International ROE % Calculation

Ascentage Pharma Group International's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-1012.442/( (456.354+66.083)/ 2 )
=-1012.442/261.2185
=-387.58 %

Ascentage Pharma Group International's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-1144.718/( (645.206+66.083)/ 2 )
=-1144.718/355.6445
=-321.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Ascentage Pharma Group International  (HKSE:06855) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-1144.718/355.6445
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1144.718 / 173.436)*(173.436 / 2963.3095)*(2963.3095 / 355.6445)
=Net Margin %*Asset Turnover*Equity Multiplier
=-660.02 %*0.0585*8.3322
=ROA %*Equity Multiplier
=-38.61 %*8.3322
=-321.87 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-1144.718/355.6445
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-1144.718 / -1166.534) * (-1166.534 / -1138.012) * (-1138.012 / 173.436) * (173.436 / 2963.3095) * (2963.3095 / 355.6445)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9813 * 1.0251 * -656.16 % * 0.0585 * 8.3322
=-321.87 %

Note: The net income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Ascentage Pharma Group International ROE % Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascentage Pharma Group International (HKSE:06855) Business Description

Traded in Other Exchanges
Address
68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company's geographical segments include the United States and Mainland China.
Executives
Ascentage Limited
Gao Sharon Xia
Guo Edward Ming
Healthquest Pharma Limited
Li Ju-yun
Wang Shaomeng
Yang Dajun
Zhai Yifan
South Dakota Trust Company Llc 2301 Trustee
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Tian Yuan 2201 Interest of corporation controlled by you
Zhao Li 2202 Interest of your spouse
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Guo Tou Chuang Xin Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you

Ascentage Pharma Group International (HKSE:06855) Headlines

No Headlines